LYNPARZA breast cancer in the adjuvant setting Japan Post-Marketing Surveillance (PMS)

Trial Identifier: D081CC00012
Sponsor: AstraZeneca
Start Date: March 2023
Primary Completion Date: December 2026
Study Completion Date: December 2026
Condition: Breast Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Japan Aomori, Japan
Japan Ehime, Japan
Japan Hokkaido, Japan
Japan Hyogo, Japan
Japan Ibaraki, Japan
Japan Ishikawa, Japan
Japan Iwate, Japan
Japan Kumamoto, Japan
Japan Mie, Japan
Japan Niigata, Japan
Japan Oita, Japan
Japan Okinawa, Japan
Japan Saga, Japan
Japan Shimane, Japan
Japan Tochigi, Japan
Japan Tottori, Japan
Japan Wakayama, Japan
Japan Yamaguchi, Japan
Japan Yamanashi, Japan